New € 239K Project Award for MEDIAN Technologies
MEDIAN Technologies has been selected to manage medical imagesin a phase II clinical study for gastric cancer sponsored by a leading Asian biotechnology company
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a new phase II clinical trial for gastric cancer sponsored by an Asian leading biotechnology company.
Within the framework of the project, imaging data will be acquired from 38 clinical sites based in four Asian countries. Anticipated total enrollment is 220 patients with a forecasted start date mid-2015. For the purposes of the study, MEDIAN will provide services for imaging data collection and quality control.
The anticipated amount for the project, awarded through MEDIAN’s alliance with its strategic CRO partner, is € 239,000 (eq. $ 310,000).
“MEDIAN has already won several Asia-based clinical trial imaging projects led by major pharmaceutical companies; however, this is our first study award with an Asian biotechnology company. It illustrates our commitment to deliver our imaging services in this region, today the world’s fastest growing region regarding oncology clinical trials”, said Nicolas Dano, Director of Business Development, Europe and Asia.
Since the beginning of 2013, MEDIAN Technologies has recorded €4.5M of orders, including €1,0M of firm orders and €3.5M of project awards [*].
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”